reticulin has been researched along with imatinib mesylate in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Campbell, L; Grigg, A; Hoyt, R; Juneja, S; Lynch, K; McNamara, C; Roberts, A; Szer, J | 1 |
| Druker, BJ; Frater, JL; Hrisinko, MA; Peterson, LC; Resta, D; Riley, MB; Tallman, MS; Variakojis, D | 1 |
| Ar, MC; Aydin, Y; Baslar, Z; Buyru, AN; Cengiz, M; Ekizoglu, S; Elverdi, T; Eskazan, AE; Ferhanoglu, B; Gulturk, E; Ongoren Aydin, S; Ozbek, U; Salihoglu, A; Senem Demiroz, A; Soysal, T; Tanrikulu Simsek, E; Tuzuner, N | 1 |
2 trial(s) available for reticulin and imatinib mesylate
| Article | Year |
|---|---|
Morphological effects of imatinib mesylate (STI571) on the bone marrow and blood of patients with Philadelphia chromosome (Ph) positive chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Benzamides; Bone Marrow Cells; Cell Count; Cytogenetic Analysis; Drug Resistance; Follow-Up Studies; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Megakaryocytes; Neutropenia; Philadelphia Chromosome; Piperazines; Pyrimidines; Reticulin; Thrombocytopenia; Treatment Outcome | 2003 |
Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.
Topics: Antineoplastic Agents; Benzamides; Biopsy; Bone Marrow; Cytogenetic Analysis; Drug Resistance; Fibrosis; Fusion Proteins, bcr-abl; Histiocytes; Humans; Hyperplasia; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Megakaryocytes; Piperazines; Pyrimidines; Reticulin; Reverse Transcriptase Polymerase Chain Reaction | 2003 |
1 other study(ies) available for reticulin and imatinib mesylate
| Article | Year |
|---|---|
Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Female; Fibrosis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Prognosis; Reticulin; Treatment Outcome; Young Adult | 2016 |